Amgen Announces License Agreement with Yeda Research and Development Company Ltd.; License Agreement Accords Amgen Freedom to Operate Under '866 Patent Read more about Amgen Announces License Agreement with Yeda Research and Development Company Ltd.; License Agreement Accords Amgen Freedom to Operate Under '866 Patent
Amgen to Acquire Avidia, a Privately Held Biopharmaceutical Company in the San Francisco Bay Area Read more about Amgen to Acquire Avidia, a Privately Held Biopharmaceutical Company in the San Francisco Bay Area
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer Read more about FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer
Amgen Introduces Comprehensive Financial Assistance Programs for Cancer Patients Read more about Amgen Introduces Comprehensive Financial Assistance Programs for Cancer Patients
Amgen Names Thomas Flanagan Senior Vice President and Chief Information Officer Read more about Amgen Names Thomas Flanagan Senior Vice President and Chief Information Officer
Amgen Presents Denosumab and Sclerostin Antibody Data at American Society for Bone and Mineral Research Annual Meeting; Data Suggest the Potential for Targeting the Key Proteins, RANK Ligand and Sclerostin, for Bone Loss Conditions Read more about Amgen Presents Denosumab and Sclerostin Antibody Data at American Society for Bone and Mineral Research Annual Meeting; Data Suggest the Potential for Targeting the Key Proteins, RANK Ligand and Sclerostin, for Bone Loss Conditions
Amgen Launches Aranesp(R) (Darbepoetin Alfa) Prefilled SureClick(TM) Autoinjector for Treatment of Anemia Associated with Chemotherapy and Chronic Kidney Disease Read more about Amgen Launches Aranesp(R) (Darbepoetin Alfa) Prefilled SureClick(TM) Autoinjector for Treatment of Anemia Associated with Chemotherapy and Chronic Kidney Disease
Amgen's Second Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 19 Percent to $1.05; GAAP Earnings Per Share of 1 Cent Reflects $1.1 Billion One-Time Write-Off of In-Process R&D Related to Abgenix Acquisition Read more about Amgen's Second Quarter 2006 Adjusted Earnings Per Share, Excluding Stock Option Expense, Increased 19 Percent to $1.05; GAAP Earnings Per Share of 1 Cent Reflects $1.1 Billion One-Time Write-Off of In-Process R&D Related to Abgenix Acquisition
Amgen Announces EVOLVE Trial(TM) To Investigate Impact of Sensipar(R)/Mimpara(R) (cinacalcet HCl) on Mortality and Cardiovascular Morbidity in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease Receiving Dialysis Read more about Amgen Announces EVOLVE Trial(TM) To Investigate Impact of Sensipar(R)/Mimpara(R) (cinacalcet HCl) on Mortality and Cardiovascular Morbidity in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease Receiving Dialysis
